| Yanan Ge,Zhendong Zheng,Zhaozhe Liu,Jianing Qiu,Xiaodong Xie. Effect of etoposide plus thalidomide as maintenance therapy on progression-free survival of elderly patients with advanced non-small cell lung cancer. Oncol Transl Med, 2017, 3: 103-107. |
| 拉司太特胶囊联合沙利度胺维持治疗对晚期非小细胞肺癌无病生存期的影响 |
| Effect of etoposide plus thalidomide as maintenance therapy on progression-free survival of elderly patients with advanced non-small cell lung cancer |
| Received:November 28, 2016 Revised:June 06, 2017 |
| DOI：10.1007/s10330-016-0207-7 |
| 中文关键词: 依托泊苷;沙利度胺;晚期;非小细胞肺癌;维持治疗 |
| 英文关键词: etoposide; thalidomide; advanced non-small cell lung cancer (NSCLC); maintenance therapy |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Yanan Ge | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China | Gynpl_a@163.com | | Zhendong Zheng | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China | | | Zhaozhe Liu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China | | | Jianing Qiu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China | | | Xiaodong Xie* | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China | doctor_xxd@163.com |
|
| Hits: 10159 |
| Download times: 11387 |
| 中文摘要: |
| 目的 评估拉司太特胶囊联合沙利度胺维持治疗晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)的有效性和安全性。方法 收集沈阳军区总医院2014年1月至2016年1月经过含铂类一线化疗4-6周期且疾病控制稳定的晚期非小细胞癌患者64例。根据维持治疗方法不同,分为拉司太特胶囊联合沙利度胺(治疗组,n=32)和最佳支持治疗(对照组,n=32)。比较两组疾病控制情况和无进展生存期(progression-free survival, PFS)。结果 治疗组和对照组的近期疗效疾病客观缓解率(Objective Response Rate, ORR)分别为31.3%和3.1%,疾病控制率(Disease ControR rates, DCR)分别为71.9%比31.3%。两组中位PFS分别为6.0个月(95%CI=4.3-7.9个月)和3.2个月(95%CI =2.6-3.8个月)。治疗组的副作用包括骨髓抑制,胃肠道毒性、肝功能损害。结论 拉司太特胶囊联合沙利度胺维持治疗能够延长晚期非小细胞肺癌患者的无进展生存期,毒副反应可耐受。 |
| 英文摘要: |
| Objective?The aim of the study was to evaluate the efficacy and safety of etoposide plus thalidomide as maintenance therapy for elderly patients with advanced non-small cell lung cancer (NSCLC) without disease progression after first-line chemotherapy.
Methods?After four to six cycles of platinum-based first-line therapy, 64 elderly patients with advanced NSCLC without disease progression who were treated in the General Hospital of Shenyang Military Region (China) from 2014 to 2016 were enrolled in this study. According to the different maintenance treatment methods, patients were divided as having received etoposide plus thalidomide therapy (treatment group, n = 32) and best supportive care (control group, n = 32). Disease control and progression-free survival (PFS) were compared between the two groups.
Results?The recent curative effect objective response rates of the treatment group and the control group were 31.3% and 3.1%, respectively, and the disease control rates were 71.9% and 31.3%, respectively. The Kaplan-Meier survival curves of the two groups were significantly different (χ2 = 26.532, P = 0.001). The median PFS for the treatment group and control group was 6.0 months [95% confidence interval (CI) = 4.3–7.9 months] and 3.2 months (95% CI = 2.6–3.8 months), respectively. The side effects in the treatment group included hematologic abnormalities, gastrointestinal toxicity, and impaired liver function, which were relieved after symptomatic support therapy and drug withdrawal.
Conclusion?Etoposide plus thalidomide as maintenance therapy is associated with a significantly longer PFS with tolerable toxicity for elderly patients with advanced NSCLC.
|
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|